Unique ID issued by UMIN | UMIN000047788 |
---|---|
Receipt number | R000054481 |
Scientific Title | Exploratory Clinical Study on Combination Therapy with Anamorelin and Component Nutrients for Cancer Cachexia Complicated by Pancreatic Cancer |
Date of disclosure of the study information | 2022/05/20 |
Last modified on | 2022/05/19 19:58:37 |
Exploratory Clinical Study on Combination Therapy with Anamorelin and Component Nutrients for Cancer Cachexia Complicated by Pancreatic Cancer
Evaluation of the Efficacy of Anamorelin and Component Nutrient Combination Therapy for Pancreatic Cancer Cachexia
Exploratory Clinical Study on Combination Therapy with Anamorelin and Component Nutrients for Cancer Cachexia Complicated by Pancreatic Cancer
Evaluation of the Efficacy of Anamorelin and Component Nutrient Combination Therapy for Pancreatic Cancer Cachexia
Japan |
pancreatic carcinoma
Hepato-biliary-pancreatic medicine |
Malignancy
NO
To evaluate the clinical significance of anamorelin and component nutritional combination therapy in pancreatic cancer patients with cancer cachexia.
Efficacy
muscle mass:On CT images, the total skeletal muscle mass at the level of the third lumbar vertebrae is measured using SYNAPSE VINCENT.
STAS,weight gain,grip strength
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Anamorelin 100 mg/day, upon waking
Elental 600 kcal/day
These will be administered for 12 weeks and evaluated.
After 13 weeks, patients will be followed up with or without medication until the final outcome.
20 | years-old | <= |
95 | years-old | > |
Male and Female
Patients with pancreatic cancer complicated with pre-cachexia or cachexia who are undergoing treatment at our hospital.
Patients must be between 20 and 95 years of age at the time of enrollment.
Written consent for participation in the study has been obtained from the subjects themselves.
Patients with a history of other cancers, and who have been treated for these cancers within 1 year.
Patients with liver disease
Cases in which the patient is pregnant, under 20 years of age, or unable to give consent
Cases in which the patient has requested to withdraw consent by disclosing information.
Other research subjects whom the principal investigator or physician in charge deems inappropriate for the safe implementation of this study.
100
1st name | Takeshi |
Middle name | |
Last name | Ogura |
Osaka Medical and Pharmaceutical University
2nd Department of Internal Medicine
5690801
2-7, Daigakumachi, Takatsuki City, Osaka
0726831221
oguratakeshi0411@yahoo.co.jp
1st name | Atsushi |
Middle name | |
Last name | Okuda |
Osaka Medical and Pharmaceutical University
2nd Department of Internal Medicine
5690801
2-7, Daigakumachi, Takatsuki City, Osaka
0726831221
ubuntu_koromo@yahoo.co.jp
Osaka Medical and Pharmaceutical University
Osaka Medical and Pharmaceutical University
Other
Osaka Medical and Pharmaceutical University Research Ethics Committee
2-7, Daigakumachi, Takatsuki City, Osaka
0726831221
rinri@ompu.ac.jp
NO
2022 | Year | 05 | Month | 20 | Day |
Unpublished
Preinitiation
2021 | Year | 07 | Month | 21 | Day |
2021 | Year | 08 | Month | 19 | Day |
2021 | Year | 09 | Month | 01 | Day |
2024 | Year | 09 | Month | 01 | Day |
2022 | Year | 05 | Month | 18 | Day |
2022 | Year | 05 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054481
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |